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In toxicology, international classification systems focus on single intoxicants as the 
cause of death. It is, however, well known that very few drug related deaths are 
caused by a single substance and that information concerning the drug 
concentrations as well as the combinations of drugs are essential in order to 
ascertain the cause of death. The aim of the study was to assess whether those 
prone to fatal intoxications differ significantly from chronic drug users - in terms of 
demographics and drug exposure patterns. 
Material and Methods 
Fatal psychoactive drug intoxications in Norway during 2012, where a forensic 
autopsy including toxicological analysis were performed, were included. Analytical 
findings in blood were compared with concentrations in blood from apprehended 
drivers under the influence of drugs and ethanol (DUID) during the same time period. 
The opioid and benzodiazepine concentrations were assessed as morphine and 
diazepam equivalents, respectively, in order to compare concentrations across the 
different groups. 
Results 
A total of 194 autopsy cases and 4,811 DUID cases were included. Opioids were 
detected in around 90% of the drug intoxication cases, but in only 16% of the DUID 
cases. The number of substances detected in fatal intoxications was 4.9 compared to 
2.4 in the DUID cases. The total opioid concentrations were significantly higher in the 
fatal intoxication cases compared to DUID cases (229 ng/mL versus 56.9 ng/mL 
morphine equivalents, respectively). Benzodiazepines were detected in 90% of the 
fatal cases. Only one fatal opioid mono-intoxication was found; a case with a very 
high methadone concentration (1238 ng/mL). 
Discussion 
Mono-intoxication with heroin was not seen in any of the fatal intoxications in Norway, 
and single drug intoxications were rare (1.5%). Fatal intoxications were caused by a 
combination of drugs with significantly more substances as well as higher total drug 
concentrations among the fatal cases compared to the DUID cases. The combination 




The total load of drugs influence the degree of intoxication and the total concentration 
level must be considered, including the total number of substances. Our findings 
imply that international statistics regarding an opioid being the main intoxicant should 
have a shift in focus towards combinations of drugs (especially opioids and 
benzodiazepines) as a major risk factor for fatal drug overdoses. 
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Both national and international statistics indicate opioids to be the leading cause of 
fatal intoxications in Norway (1-3). Heroin is the most commonly used opioid in 
Norway, and it is estimated that approximately 85% of the heavy opioid users inject 
heroin (1). Injection of heroin is a drug administration route prone to cause fatal 
overdoses, and could partly explain the high overdose rate seen in Norway compared 
with many other European countries where injecting heroin is less common (2, 4). 
In the Global Burden of Health calculations, misuse of illicit drugs is ranked as the 
10th leading risk factor for a reduction of disability-adjusted life years (DALYs) in 
Norway in 2015 (5). More than 41 000 years of life lost (YLLs) are attributed to the 
use of alcohol and illicit drugs, and ranks as the 5th leading risk factor for early death 
in Norway in 2015; for the ages 15 to 49 years it is regarded as the leading 
contributor to early death. Fatal opioid-related intoxications among men are stated to 
be a strong driving force for the YLLs (5, 6). 
Drug induced deaths are classified according to the presence of drugs in toxicological 
samples, and most countries use international classification systems, like the ICD 
(International Classification of Diseases) (7), for diagnostic purposes. A single 
substance is typically chosen as the main intoxicant, and positive findings of e.g. 
morphine/heroin or methadone, lead to the classification of a heroin or methadone 
related death, respectively, by hierarchal traditions. However, in the majority of the 
fatal intoxications, several drugs may contribute to death (8-11). There is consistent 
knowledge about the dose-response relationship for specific psychoactive 
substances and the risk of intoxication is highly related to the drug concentrations, 
still with individual variations (12). A considerable overlap between concentrations of 
drugs of abuse seen in living persons and in fatal overdose cases has been reported 
(12). Possible explanations include the administration route, drug combinations, 
variable tolerance and metabolism within and between individuals, and post mortem 
redistribution of drugs. 
In order to prevent fatal drug intoxications and to develop appropriate preventive 
strategies, it is important to be aware of and further understand the interrelationships 
between risk factors for intoxication, and especially whether such increased risk 




The aim of the study was to assess whether those who died from intoxications 
differed significantly from a group considered as chronic drug users regarding 
demographical data, choice of drug(s), and blood concentrations. 
Materials and Methods 
Material 
All instances of fatal intoxications in Norway subject to forensic autopsy during 2012 
were assessed according to inclusion criteria described by Simonsen et al. (13). The 
cause of death was determined to be intoxication. Mono-intoxications with ethanol 
were excluded. 
According to the Norwegian Criminal procedure Act, a forensic autopsy is only 
mandatory where death is suspected to have been caused by a punishable act, in 
cases where the deceased is unidentified or among deceased younger than 18 
years. However, a forensic autopsy is also recommended in suicides, accidents and 
cases of sudden, unexpected death. Further, the doctor is obliged to report such 
cases to the police, also including cases of suspected drug related deaths (14). A 
forensic autopsy is thus not performed in all suspected intoxication deaths, but it is 
estimated that approximately 90% of the cases are subject to such an autopsy (15). 
Whole blood samples collected during autopsies were, for 95% of the cases, 
analysed at the Department of Forensic Sciences, Oslo University Hospital (OUH). 
The remaining 5% were analysed at the Department of Clinical Pharmacology, St. 
Olavs Hospital – Trondheim University Hospital. 
In fatal overdoses, several drugs are often detected in blood (16). We do not know 
whether the pattern of number of drugs and concentrations reflect regular drug use.  
Therefore, we wanted to compare findings among deceased with findings among a 
population of living drug users. The preferred comparable data would be findings 
from non-fatal intoxications, but such data are not available. The comparison with 
DUID cases was considered the second best option because drivers apprehended by 
the police often are chronic drug users, reflected in the fact that they frequently test 
positive for more than one psychoactive substance in high concentrations (17). In a 
study of apprehended drivers in Norway one or more drugs were detected in 
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concentrations above the limit for graded sanction corresponding to 0.12% blood 
alcohol concentration (BAC) in about 40% of the cases (18). Other studies have 
shown that a significant number of drivers killed in traffic accidents had been 
apprehended by the police due to impaired driving at previous occasions (19). The 
DUID cases in the present study thus consist mainly of persons with significant drug 
use, and represent, to a certain extent, individuals with characteristics similar to those 
of fatal drug deaths in terms of dangerous/problematic drug use. 
Samples from drivers apprehended by the police nationwide due to suspected driving 
under the influence of drugs and ethanol (DUID) in 2012, were included for 
comparison of drugs involved, drug concentrations and demographic data. All DUID 
cases were analysed according to a standard protocol at OUH for ethanol and 
approximately 40 medicinal substances and illicit drugs. 
Samples 
From the autopsy cases, only cases with whole blood samples collected from the 
femoral vein were included in the study. The samples were collected into 20 mL 
Steriline®  tubes (Bibby Sterilin, Staffordshire, UK), containing 0.3 ml 67 % (w/v) 
potassium fluoride (KF) solution as a preservative. Blood obtained from a peripheral 
vein from DUID subjects were collected into 5 mL Vacutainer® tubes, containing 20 
mg NaF (a preservative) and 143 IU of heparin (BD Vacutainer Systems, Belliver 
Industrial Estate, Plymouth, UK). 
Analyses 
The samples were analysed shortly after arrival at the laboratories. Figure 1 
illustrates the distribution and analytical principles of the sample handling. 
The autopsy samples received at OUH were analysed for around 100 different 
psychoactive compounds in total. Ethanol screening was performed by an enzymatic 
method (20) and a positive finding was confirmed by gas chromatography (21). 
Amphetamines, cannabinoids, cocaine metabolites, and opiates were screened for 
by an immunological method (22). Screening for other drugs was performed using 
high-performance liquid chromatography with mass spectrometry detection (LC-MS) 
(23). Confirmatory analyses were done by gas chromatography with mass 
spectrometry (GC-MS) or LC-MS (23-26). 
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In the autopsy samples received at St. Olavs Hospital, whole blood was subjected to 
specific analyses for alcohols (ethanol, methanol, isopropanol, acetone) using a 
headspace GC–MS method, and specific analyses for benzodiazepines (diazepam, 
nordiazepam, oxazepam, nitrazepam, 7-aminonitrazepam, flunitrazepam, 7-
aminoflunitrazepam, clonazepam, 7-aminoclonazepam, alprazolam, midazolam), 
opioids (morphine, codeine, ethylmorphine, oxycodone, fentanyl, buprenorphine, 
morphine-3-glucuronide (M3G), morphine-6-glucuronide (M6G), 6-MAM) and 
amphetamines (amphetamine, methamphetamine, MDMA and MDA) using LC–MS 
methods. In addition, blood specimens were screened against comprehensive drug 
libraries (National Institute of Standards and Technology Mass Spectral Library, 
Forensic Toxicology Retention Time Locking Database/Library and 
Pfleger/Maurer/Weber Drugs and Pesticides Library for Toxicology) with a GC–MS 
method. When available, urine was also screened for drugs of abuse using LC–MS 
and GC-MS methods. Positive screening results, as well as explicit information about 
drug use in the case histories, were confirmed by specific analyses in blood using 
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HPLC-MS/MS (incl. UHPLC-MS/MS) 
Figure 1: The distribution and analyses of the samples 
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DUID samples (all analysed at OUH) were screened for ethanol by an enzymatic 
method (20) and the ethanol concentration was quantified using headspace GC-FID 
(22). High-performance liquid chromatography with tandem mass spectrometry (LC-
MS/MS) was used for analysing a selection of illicit drugs, sedatives, hypnotics and 
analgesics (27). The confirmation analyses of tetrahydrocannabinol (THC) were done 
by GC-MS (24), for amphetamine and methamphetamine by GC-MS (26), for 
benzodiazepines by LC-MS/MS (28), for heroin and its metabolites by LC-MS/MS 
(29), for other opiates by ultra-high liquid chromatography with tandem mass 
spectrometry (UHPLC-MS/MS) (30), for gamma-hydroxybutyrate (GHB) by UHPLC-
MS/MS (31), for lysergic acid diethylamide (LSD) by UHPLC-MS/MS (32), and for z-
hypnotics by UHPLC-MS/MS (33). 
Drug groups 
The drugs were classified in drug groups for comparison of drug findings- and 
concentrations. The definitions of the groups are presented below. 
Opioids: Included opioids were heroin/morphine, methadone, buprenorphine, 
oxycodone, fentanyl, hydromorphone, codeine, tramadol and AH-7921. 
Heroin is rapidly metabolised to 6-monoacetylmorphine (6-MAM) in blood and further 
into morphine after intake. Consequently, if 6-MAM is not detected, it is impossible to 
determine whether heroin or morphine was used. We have therefore defined cases 
with morphine in blood and/or 6-MAM in blood/urine without a high codeine 
concentration as heroin/morphine cases on the basis of the toxicological analysis. 
Codeine was regarded as a codeine-case if there was no concomitant morphine or if 
a concomitant morphine concentration was <10% of the codeine concentration (34).  
If the concomitant morphine concentrations were >10%, the cases were not regarded 
as codeine cases. Codeine was regarded as a trace amount/pollution if concomitant 
6-MAM in blood or urine was present. 
Benzodiazepines: Included benzodiazepines were clonazepam, 7-aminoclonazepam, 
diazepam/nordiazepam, alprazolam, oxazepam, etizolam, phenazepam, 
flunitrazepam, lorazepam, and nitrazepam. The z-hypnotics zolpidem and zopiclone 
were added to benzodiazepines due to their similar sedating effects. 
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Amphetamine/methamphetamine: Methamphetamine is partly metabolised into 
amphetamine in vivo (35). It is not possible to differentiate between intake of pure 
methamphetamine and intake of a mixture of methamphetamine and amphetamine. 
These findings were therefore summarized, and denoted 
“amphetamine/methamphetamine”. 
Cannabis: Detection of THC in blood above the detection limit was defined as a 
positive THC-sample. 
Ethanol: Ethanol was only included with concomitant findings of the metabolites ethyl 
glucuronide or ethyl sulphate in the autopsy cases. 
Other substances: Substances not eligible to any of the above mentioned groups 
were called “other substances”. This group consists of a variety of substances with a 
broad spectrum of effects, but the number of cases where these drugs were found 
was low compared to the other groups. Further analysis of these findings were thus 
considered unwarranted. Substances in this group were: 2-phenylethylamine, 
cocaine, 3,4-methylenedioxyamphetamine (MDA), 3,4-
methylenedioxymethamphetamine (MDMA), para-methoxyamphetamine (PMA), 
para-methoxymethamphetamine (PMMA), methylphenidate,  methoxetamin, 
alimemazine, promethazine, amitriptyline, nortriptyline, bupropion, citalopram, 
duloxetine, fluoxetine, mianserin, mirtazapine, paroxetine, sertraline, trimipramine, 
venlafaxine, phenytoin, carbamazepine, lamotrigine, pregabalin, valproic acid, 
hydroxyzine, ketamine, flupenthixol, chlorprothixene, clozapine, levomepromazine, 
olanzapine, perphenazine, quetiapine, risperidone and LSD.  
All of the abovementioned drugs are counted as psychoactive substances in the 
“Results” section. 
Compilation of drug concentrations  
The opioid and benzodiazepine concentrations were assessed as morphine and 
diazepam equivalents, respectively, in order to compare concentrations across the 
different groups (Table 1). Clonazepam is metabolised into the inactive metabolite 7-
aminoclonazepam post mortem (36), and clonazepam itself is rarely detected in 
autopsy cases. The concentration of 7-aminoclonazepam is therefore regularly used 
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as a proxy for interpretation of clonazepam concentrations in forensic toxicology 
cases.  
Table 1: Conversion factors for morphine- and diazepam equivalents 
Compound Conversion factor 



















For the DUID cases, only clonazepam is measured and used in evaluation of 
impairment, since 7-aminoclonazepam is inactive and not relevant for evaluation of 
impairment. 
Diazepam equivalents (37-39) were used to calculate the total benzodiazepine 
concentration for comparison of concentrations from the fatal intoxication cases with 
the DUID cases (40). For the autopsy cases, clonazepam was not included in the 
calculation, only 7-aminoclonazepam, and for the DUID cases the metabolite was not 
measured, hence only clonazepam-levels were available for consideration and the 
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concentration was multiplied with 48 to mimic the clonazepam-concentration. For 
nitrazepam and flunitrazepam, only the parent compounds were included in the 
calculation in both groups. 
Measured levels of methadone, oxycodone and morphine-6-glucuronide (M6G), were 
expressed as morphine equivalents (40-44). Morphine and M6G have similar effects, 
but somewhat different potency, and M6G has lower depressant effects on the 
respiration centre (45). In the present study M6G is regarded as a product of 
heroin/morphine intake and the concentrations of M6G and morphine considered as 
equipotent. A number of studies show that M6G is psychoactive (45); therefore it is 
included in order to evaluate the effects of opioid concentrations. 
Statistical methods 
Differences in the number of psychoactive substances and concentrations were 
assessed using Wilcoxon Rank Sum Test in SPSS Statistics Version 22 and 23 (IBM 
Corporation, Armonk, NY). 
Ethics 
Approval has been achieved from the Regional Ethics Committee, 2013/786 
REK sør-øst B, and from the Public Prosecutor at the Office of the Director of Public 
Prosecutions, 2013/01346-002 AGJ/ggr 639.2. Only anonymised data is presented in 
tables and figures. 
Results 
A total of 194 fatal intoxication cases and 4,811 DUID cases were included. Mean 
age, age and gender distribution and mean number of drugs detected are presented 
in Table 2. The age distribution is somewhat lower among the DUID cases, with 57% 
of the cases being younger than 35 years versus 42% of the autopsy cases. Men 
were overrepresented in both groups, and the prevalence of men was highest among 





Table 2: Demographic data for both groups 










Autopsy 194 37.8 18-66 79 4.9 1-12 
DUID 4,811 34.1 14-79 86 2.6 1-10 
*incl. ethanol 
 
Toxicological findings in autopsy cases 
Among the autopsy cases, only three (1.5%) mono-intoxications were found (Figure 
2). 
 
Figure 2: Number of psychoactive substances detected in the autopsy and the DUID group. 
 
Opioids were found in 179 (92%) of the cases, and benzodiazepines in 175 (90%) 
cases. Amphetamine/methamphetamine was found in 85 (44%) cases and THC in 77 
(40%) cases. Ethanol was detected in 28 (14%) cases. “Other substances” were 
detected in 101 (52%) cases (Figure 3). 
Figure 3 shows in more detail the ten most frequently detected substances in the 
autopsy group, with heroin/morphine (as indicated by findings of 6-MAM and/or 
































respectively; total of 54%) being the most frequent substances found. Other 
frequently found substances were diazepam/nordiazepam (44% and 47% of the 
cases, respectively; total of 50%), amphetamine and/or methamphetamine (44 % of 




Figure 3: The most frequently found substances in fatal intoxications in 2012 (grey bars), 
along with total percentage of the positive cases for the different drug groups (shaded bars). 
 
Of the three mono-intoxication cases, relatively high concentrations of 
amphetamine/methamphetamine (446 ng/mL and 343 ng/mL) were found in two 
cases; the third case had a methadone concentration of 1238 ng/mL. In the sixteen 
cases with two different substances opioids were detected in 13 cases, 
benzodiazepines in 9, THC in 3, ethanol in 2, amphetamine/methamphetamine in 2 
cases, and single cases with perphenazine, sertraline, and valproic acid. All of the 
remaining autopsy cases were poly drug cases with substances from at least two 
different drug groups. 
Toxicological findings in all cases 
The autopsy cases were positive for more psychoactive substances than the DUID 
cases (p<0.001; Figure 2). 
Higher concentrations of benzodiazepines and opioids were found in the autopsy 
cases (p<0.001), whereas higher concentrations of THC (p=0.005) and ethanol 














concentrations of amphetamine/methamphetamine between the two groups (Table 
3). The mean diazepam concentration in the DUID cases was nearly three times 
higher than in the autopsy cases, whereas the nordiazepam concentration was twice 
as high. The median concentrations of amphetamine/methamphetamine were high in 
both groups; however, amphetamine/methamphetamine is rarely associated with 
fatal mono-intoxication (46-48).             
Table 3: Median, minimum and maximum concentrations (ng/mL); autopsy and DUID cases 





% Median Min Max 
Valid 
N 
% Median Min Max P= 
Benzodiazepines* 173 89.2 1.76 5.69 45.9 2,887 60.0 1.03 28.5 28.2 <0.001 
Opioids** 159 82.0 211 2.85 3.91 403 8.4 40.0 6.56 2.60 <0.001 
Amphetamine/ 
methamphetamine 
85 43.8 385 104 5.15 1,997 41.5 343 27.0 5.68 0.386 
THC 77 39.7 2.30 0.31 157 1,823 37.9 2.96 0.63 72.3 0.005 
Ethanol (‰) 28 14.4 0.85 0.10 4.1 1,698 35.3 1.4 0.04 4.3 0.040 
* Diazepam equivalents of alprazolam, nordiazepam, diazepam, fenazepam, flunitrazepam, clonazepam, 7-
aminoclonazepam, lorazepam, nitrazepam, oxazepam, zolpidem, and zopiclone. The autopsy cases excluded 
clonazepam, whereas the DUID cases were not analysed for 7-aminoclonazepam 
** Morphine equivalents of morphine, M6G, methadone, oxycodone 
 
Heroin/morphine cases 
Heroin/morphine and one or more benzodiazepines was the most frequent drug 
combination found among the autopsy cases. In total, benzodiazepines were 
detected in 94 (89%) of the 106 heroin/morphine positive cases, with 7-
aminoclonazepam and/or diazepam/nordiazepam being the most frequently found 
benzodiazepines present in 79 of the heroin/morphine positive autopsy cases. 
Stimulants were detected in 48 cases (45%), whereas THC was found in 35 cases 
(33%). Only 14 (13%) of the 106 heroin/morphine positive cases were positive for 
ethanol. Other substances were detected in 42% of cases. Between two and 12 
different substances were found in each heroin/morphine-positive case, with a mean 
number of 4.9 substances per case. 
Heroin/morphine was found in less than 5% of the DUID cases. Among these, the 
same pattern of combinations was seen, with almost 80% of heroin/morphine positive 
cases testing positive for benzodiazepines (especially clonazepam and diazepam, 
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but also alprazolam). The heroin/morphine positive DUID cases were to a lesser 
degree associated with stimulants (34%) and other substances (9%) than the 
heroin/morphine positive autopsy cases. In the heroin/morphine-positive DUID cases 
the total number of different substances varied between one and nine, with a mean 
number of 3.6 substances per case. 
As presented in Table 4, when only taking into consideration heroin/morphine-
positive cases, there were still significant differences between autopsy and DUID 
cases when considering concentrations of benzodiazepines (p=0.036) and opioids 
(p<0.001), with autopsy cases having the highest concentrations. For THC, there 
were higher concentrations among the DUID heroin/morphine-positive cases than 
among the autopsy cases. There were no significant differences in 
amphetamine/methamphetamine and ethanol concentrations. 
Table 4: Median, minimum and maximum concentrations (ng/mL) in heroin/morphine-positive 
cases; autopsy and DUID cases.  
 




cases 106 230 
 Valid 
N 
% Median Min Max 
Valid 
N 
% Median Min Max p= 
Benzodiazepines*  92 86.8 2.13 5.69 43.6 182 79.1 1.64 71.2 15.5 0.036 
Opioids**  106 100 225 2.85 3.91 218 94.8 27.8 7.99 2.60 <0.001 
Amphetamine/ 
methamphetamine 
47 44.3 303 10.4 3.20 76 33.0 172 31.1 2.18 0.131 
THC 35 33.0 1.79 0.35 15.4 74 32.2 2.69 0.79 18.2 0.049 
Ethanol (‰) 14 13.2 1.0 0.10 2.2 24 10.4 1.0 0.04 2.2 0.586 
* Diazepam equivalents of alprazolam, nordiazepam, diazepam, fenazepam, flunitrazepam, clonazepam, 7-
aminoclonazepam, lorazepam, nitrazepam, oxazepam, zolpidem, and zopiclone. The autopsy cases excluded the 
concentrations of clonazepam, whereas the DUID cases were not analysed for 7-aminoclonazepam. 
** Morphine equivalents of morphine, M6G, methadone, oxycodone. 
 
Discussion 
Our study shows that in approximately 90% of the fatal intoxications, opioids were 
detected, but as a single intoxicant in only one case (0.5%). The median 
concentration of morphine equivalents was 5 times higher in the fatal intoxications 
cases than in the DUID cases (Table 3). Benzodiazepines were detected in 
approximately 90% of the opioid positive fatal cases, indicating that opioids rarely 
were the sole causative agents in these deaths. Benzodiazepines alone did not 
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cause fatalities in any cases. The median diazepam equivalent concentration was 
higher in the fatal intoxication cases than in DUID cases, even though the mean 
concentrations of diazepam and nordiazepam were highest among the DUID cases. 
The estimated equivalence concentrations for the benzodiazepines in the autopsy 
cases were thus based mainly on clonazepam intake prior to death. 
Drug combinations  
A combination of more than one drug was frequently found in both DUID and autopsy 
cases. The mean number of drugs per case was almost twice as high among the 
fatal intoxication cases, thus the number of ingested drugs seems to increase the 
death risk. A previously published study by Sun et al., and an accompanying editorial 
in the BMJ, support our findings, and emphasise the increased risk of death when 
opioids and benzodiazepines are used concomitantly (49, 50). Not surprisingly, the 
number of opioid intoxications was high in the present study, but the fact that 
benzodiazepines were concomitantly detected in as many as 90% of these cases, is 
an important finding. The most frequently found drugs in both autopsy and DUID 
cases were opioids, benzodiazepines, THC and amphetamine/methamphetamine in 
different combinations. 
Concentrations  
Interpretation of concentrations of clonazepam/7-aminoclonazepam is difficult in the 
autopsy cases, due to post mortem degradation of clonazepam and the formation of 
7-aminoclonazepam (36). The 7-aminoclonazepam concentrations found in the 
autopsy cases were more than twice as high as the clonazepam concentrations in 
DUID cases, indicating a more widespread exposure for clonazepam among the 
autopsy cases. 
Limitations 
There are several limitations when using routine cases for research purposes in order 
to throw light on drug intoxication deaths. However, these available data are 
important in order to achieve more knowledge about the lethal drug use patterns in 
order to prevent drug overdoses. 
The estimated equivalence concentrations of opioids did not include all of the 
analysed opioids, which might underestimate the total load of opioids. However, the 
most frequently detected opioids (morphine and methadone) were included in the 
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calculations. The other opioids were detected in less than 15% of the cases and 
always in low concentrations. 
The equivalence concentrations of benzodiazepines were limited by the fact that the 
nitro benzodiazepines are unstable post mortem (51). Despite that, the equivalence 
concentrations were significantly higher among the fatal intoxication cases. 
Furthermore, post mortem redistribution and formation/degradation make post 
mortem findings more challenging to interpret than the DUID findings. The 
concentrations might not be representative for the the ante mortem concentrations 
(52). The time from drug administration until death will affect the degree of 
metabolism and excretion prior to death (36, 51, 53). The time period between death 
and autopsy may vary greatly, and within this period, changes in drug concentrations 
in the blood samples are likely to take place. Changes in drug concentrations can 
also be seen in vitro after sample collection (34). 
Our study included blood concentrations, but information regarding drug intake is 
missing. The data can therefore not be used to assess the dosage that lead to 
intoxication. 
Conclusions 
Our study has confirmed that fatal intoxications by single substances are rare in 
Norway (1.5%) and mono-intoxication with heroin was not seen in any of the fatal 
intoxications that underwent forensic autopsy in 2012. Fatal intoxications were 
caused by a combination of drugs, with significantly more substances as well as 
higher total drug concentrations among the autopsy cases. Heroin/morphine are the 
most frequently detected drugs in fatal intoxications, often combined with 
benzodiazepines. The combination of opioids and benzodiazepines seemed to 
represent a particular increased risk of death. 
It is important to consider the concentrations of all different psychoactive substances 
when these cases are categorised for determining the cause of death, since it is very 
rare that one intoxicant alone causes death. Furthermore, interpretation of the 
concentrations must be done with caution in poly-intoxications since reference 
concentrations often are based on mono-intoxications. 
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These results imply that international statistics regarding an opioid being the main 
intoxicant should have a shift in focus towards combinations of drugs (especially 
opioids and benzodiazepines) as a major risk factor for fatal drug overdoses. 
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Table 3: Median, minimum and maximum concentrations (ng/mL); autopsy and DUID cases 





% Median Min Max 
Valid 
N 
% Median Min Max P= 
Benzodiazepines* 173 89.2 1765 5.69 45922 2,887 60.0 1025 28.5 28185 <0.001 
Opioids** 159 82.0 211 2.85 3910 403 8.4 40.0 6.56 2597 <0.001 
Amphetamine/ 
methamphetamine 
85 43.8 386 9.46 5112 1,997 41.5 333 29.8 5678 0.386 
THC 77 39.7 2.20 0.31 157 1,823 37.9 2.83 0.63 72.3 0.005 
Ethanol (‰) 28 14.4 0.85 0.10 4.1 1,698 35.3 1.4 0.04 4.3 0.040 
* Diazepam equivalents of alprazolam, nordiazepam, diazepam, fenazepam, flunitrazepam, clonazepam, 7-
aminoclonazepam, lorazepam, nitrazepam, oxazepam, zolpidem, and zopiclone. The autopsy cases excluded 
clonazepam, whereas the DUID cases were not analysed for 7-aminoclonazepam 
** Morphine equivalents of morphine, M6G, methadone, oxycodone 
 
 
Table 4: Median, minimum and maximum concentrations (ng/mL) in heroin/morphine-positive 
cases; autopsy and DUID cases.  
 




cases 106 230 
 Valid 
N 
% Median Min Max 
Valid 
N 
% Median Min Max p= 
Benzodiazepines*  92 86.8 2078 5.69 40997 182 79.1 1651 71.2 15459 0.036 
Opioids**  106 100 225 2.85 3910 230 100 28.0 7.99 2597 <0.001 
Amphetamine/ 
methamphetamine 
47 44.3 304 9.46 3200 76 33.0 164 31.1 2183 0.131 
THC 35 33.0 1.89 0.31 15.7 74 32.2 2.83 0.63 18.9 0.049 
Ethanol (‰) 14 13.2 1.0 0.10 2.2 24 10.4 1.0 0.04 2.2 0.586 
* Diazepam equivalents of alprazolam, nordiazepam, diazepam, fenazepam, flunitrazepam, clonazepam, 7-
aminoclonazepam, lorazepam, nitrazepam, oxazepam, zolpidem, and zopiclone. The autopsy cases excluded the 
concentrations of clonazepam, whereas the DUID cases were not analysed for 7-aminoclonazepam. 
** Morphine equivalents of morphine, M6G, methadone, oxycodone. 
 
